4.5 Article

Development of Generic Quality Indicators for Patient-Centered Cancer Care by Using a RAND Modified Delphi Method

Journal

CANCER NURSING
Volume 35, Issue 1, Pages 29-37

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/NCC.0b013e318210e3a2

Keywords

Cancer; Oncology; Patient-centered care; Quality indicators

Funding

  1. Dutch Cancer Society [KUN 2005-3207]

Ask authors/readers for more resources

Background: Despite growing attention to patient-centered care, the needs of cancer patients are not always met. Objective: Using a RAND modified Delphi method, this study aimed to systematically develop evidence-based indicators, to be used to measure the quality of patient-centered cancer care as a first step toward improvement. Methods: First, key recommendations were identified from literature and were distributed over 5 domains of patient-centered cancer care: communication, physical support, psychosocial care, after-care, and organization of care. Generic key recommendations, with best available evidence, were selected from guidelines. A multidisciplinary panel of patients and medical professionals (n = 14) rated and prioritized these recommendations in a written procedure. Subsequently, the panel discussed the recommendations at a consensus meeting. Results: Key recommendations were identified for communication (n = 32), physical support (n = 13), psychosocial care (n = 25), after-care (n = 11), and organization of care (n = 11). For all domains, recommendations based on high-level evidence were identified except for after-care and physical support. The panel developed 17 indicators concerning criteria for communication and informed consent, evaluation of communication skills, provision of information, examination of emotional health, appointment of a care coordinator, physical complaints, follow-up, rehabilitation, psychosocial effects of waiting times, and self-management. Conclusions: A set of 17 indicators for patient-centered cancer care resulted from this study. Evidence support was available for most indicators. Implications for Practice: This set provides an opportunity to measure and improve the quality of patient-centered cancer care. It is generic and therefore applies to many patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Barriers and facilitators for implementation of the SWORD evidence-based psychological intervention for fear of cancer recurrence in three different healthcare settings

Esther Deuning-Smit, Evie E. M. Kolsteren, Linda Kwakkenbos, Jose A. E. Custers, Rosella P. M. G. Hermens, Judith B. Prins

Summary: This study aimed to identify barriers and facilitators for implementing the evidence-based blended SWORD intervention in routine psycho-oncological care. The study found barriers and facilitators in six domains, including innovation, professionals, patients, social context, organization, and economic and political context. Implementation strategies should target patient, professional, organizational, and economic and political domains.

JOURNAL OF CANCER SURVIVORSHIP (2023)

Article Oncology

Quality of integrated female oncofertility care is suboptimal: A patient-reported measurement

Michelle van den Berg, Suzanne E. J. Kaal, Teska N. Schuurman, Didi D. M. Braat, Caroline M. P. W. Mandigers, Jolien Tol, Jacqueline M. Tromp, Maurice J. D. L. van der Vorst, Catharina C. M. Beerendonk, Rosella P. M. G. Hermens

Summary: A survey study was conducted to assess the current practice of female oncofertility care in cancer patients. The results showed that the quality of care is far from optimal, with low adherence to several key indicators. Improvement strategies tailored to the identified determinants and guideline-specific barriers are needed.

CANCER MEDICINE (2023)

Article Oncology

Position paper from the Endocrine Task Force of the European Organisation for Research and Treatment of Cancer (EORTC) on the management and shared decision making in patients with low-risk micro papillary thyroid carcinoma

Anna Koot, Paula Soares, Eyal Robenshtok, Laura D. Locati, Christelle de la Fouchardiere, Markus Luster, Massimo Bongiovanni, Rosella Hermens, Petronella Ottevanger, Frans Geenen, Beate Bartes, Harald Rimmele, Cosimo Durante, Els Nieveen-van Dijkum, Peep Stalmeier, Marek Dedecjus, Romana Netea-Maier

Summary: The incidence of differentiated thyroid cancer (DTC) is increasing globally, mainly due to the detection of micro papillary thyroid carcinomas (microPTCs), which often lead to overtreatment without improvement in mortality rate. Less aggressive approaches, such as active surveillance or minimally invasive treatments (MIT), have been suggested as alternatives. Patient participation in decision-making process is crucial. The Endocrine Task Force of the EORTC aims to establish consensus and provide practical suggestions for implementing shared decision making (SDM) based on scientific evidence and patients' needs.

EUROPEAN JOURNAL OF CANCER (2023)

Article Obstetrics & Gynecology

Evaluation of a web-based intervention for patients with Gestational Trophoblastic Disease: a randomized controlled trial

Minke Frijstein, Laura Blok, Marianne ten Kate Booij, Yalck Eysbouts, Nienke van Trommel, Fred Sweep, Leon Massuger, Dennis V. Hamont, Henk Schreuder, Marieke Smink, Jan Molkenboer, Peggy Vencken, Nelleke Ottevanger, Christianne Lok, Trophy Study Grp

Summary: This study investigated the effect of a web-based interactive intervention on illness perception and knowledge in women with GTD. The results showed that patients using the online tool were satisfied with the information and had higher knowledge levels compared to the control group, but illness perception did not change.

GYNECOLOGIC AND OBSTETRIC INVESTIGATION (2023)

Article Oncology

Adherence to quality indicators in chronic myeloid leukemia care: results from a population-based study in The Netherlands

Genevieve I. C. G. Ector, Inge G. P. Geelen, Avinash G. Dinmohamed, Mels Hoogendoorn, Peter E. Westerweel, Rosella P. M. G. Hermens, Nicole M. A. Blijlevens

Summary: This study shows suboptimal adherence to treatment guidelines among chronic myeloid leukemia patients, particularly in monitoring aspects. It highlights the evidence-practice gap, the need for improvement, and emphasizes the importance of real-world data.

LEUKEMIA & LYMPHOMA (2023)

Article Oncology

Evaluating the capacity of the distress thermometer to detect high fear of cancer recurrence

Esther Deuning-Smit, Jose A. E. Custers, Linda Kwakkenbos, Rosella P. M. G. Hermens, Judith B. Prins

Summary: The Distress Thermometer (DT) and its accompanying problem list have limited capacity in detecting fear of cancer recurrence (FCR), indicating a need for more effective measures to improve patient access to psychosocial care in oncology practice.

PSYCHO-ONCOLOGY (2023)

Article Oncology

Healthcare professionals' perceived barriers and facilitators of health behavior support provision: A qualitative study

Eline Bouwman, Saskia M. F. Pluijm, Iridi Stollman, Vera Araujo-Soares, Nicole M. A. Blijlevens, Cecilia Follin, Jeanette Falck Winther, Lars Hjorth, Tomas Kepak, Katerina Kepakova, Leontien C. M. Kremer, Monica Muraca, Helena J. H. van der Pal, Carina Schneider, Anne Uyttebroeck, Gertrui Vercruysse, Roderick Skinner, Morven C. Brown, Rosella P. M. G. Hermens, Jacqueline J. Loonen

Summary: This study identified education and training of healthcare professionals (HCPs) as key opportunities to improve health behavior support (HBS) for childhood cancer survivors (CCSs). Survivorship care clinics should work towards establishing well-integrated structured care with internal and external networks, including HBS being part of routine care. Proper understanding of facilitators and barriers should lead to better survivorship care for CCSs.

CANCER MEDICINE (2023)

Article Oncology

Cancer treatments touch a wide range of values that count for patients and other stakeholders: What are the implications for decision-making?

Cilla E. J. Vrinzen, Haiko J. Bloemendal, Esra Stuart, Amr Makady, Michel van Agthoven, Mariska Koster, Matthias A. W. Merkx, Rosella P. M. G. Hermens, Patrick P. T. Jeurissen

Summary: This study explores the various values involved in oncological treatments and their implications in decision-making. It finds that clinical values are not the only ones that matter, and there is a broader range of values to consider. The study suggests that recognizing the values that count can improve patient-level decision-making and support, but the implications for reimbursement decisions are less clear.

CANCER MEDICINE (2023)

Article Oncology

Patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukaemia (RODEO study): study protocol for a prospective, multicentre, single-arm trial

Melissa F. Djodikromo, Rosella P. M. G. Hermens, Bart J. F. van den Bemt, Yolba Smit, Tim M. Govers, Charlotte L. Bekker, Nicole M. A. Blijlevens

Summary: This study aims to evaluate the effectiveness of patient-guided dose reduction of tyrosine kinase inhibitors (TKI) in patients with chronic myeloid leukaemia (CML) who have reached a major or deep molecular response. The study includes 147 CML patients who will use an online patient decision aid and receive a shared decision making consultation before choosing to receive a personalised, lower TKI dose. The primary outcome is the proportion of patients with intervention failure at 12 months after dose reduction.

BMC CANCER (2023)

Article Health Care Sciences & Services

Effectiveness of digital care platform CMyLife for patients with chronic myeloid leukemia: results of a patient-preference trial

Lynn Verweij, Genevieve I. C. G. Ector, Yolba Smit, Bas van Vlijmen, Bert A. van der Reijden, Rosella P. M. G. Hermens, Nicole M. A. Blijlevens

Summary: CMyLife is an eHealth innovation co-created with and for chronic myeloid leukemia (CML) patients to improve their care, leading to increased quality of life and the opportunity for hospital-free care. It explores the effectiveness of CMyLife in terms of information provision, patient empowerment, medication compliance, molecular monitoring, and quality of life.

BMC HEALTH SERVICES RESEARCH (2023)

Article Oncology

Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer

Loek A. W. de Jong, Marie Lambert, Nielka P. van Erp, Lukas de Vries, Etienne Chatelut, Petronella B. Ottevanger

Summary: The purpose of this study was to determine the systemic exposure to cisplatin and paclitaxel following adjuvant intraperitoneal administration in patients with advanced ovarian cancer. The study found that systemic exposure to cisplatin after intraperitoneal administration is high, providing a pharmacological explanation for the high incidence of adverse events seen with this treatment regimen.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2023)

Review Oncology

A Systematic Review and Multilevel Regression Analysis Reveals the Comorbidity Prevalence in Cancer

Cilla E. J. Vrinzen, Linn Delfgou, Niek Stadhouders, Rosella P. M. G. Hermens, Matthias A. W. Merkx, Haiko J. Bloemendal, Patrick P. T. Jeurissen

Summary: Comorbidities can greatly affect cancer care, including diagnosis, treatment outcomes, and healthcare costs. Therefore, it is crucial to evaluate the prevalence and trends of comorbidities in cancer patients.

CANCER RESEARCH (2023)

Review Oncology

The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: A systematic review and meta-analysis

C. S. E. Hendrikse, P. M. M. Theelen, P. van der Ploeg, H. M. Westgeest, I. A. Boere, A. M. J. Thijs, P. B. Ottevanger, A. van de Stolpe, S. Lambrechts, R. L. M. Bekkers, J. M. J. Piek

Summary: The RAS/RAF/MEK/ERK (MAPK) pathway plays a role in ovarian carcinogenesis, particularly in low-grade serous ovarian carcinoma (LGSOC) with activating MAPK mutations. A meta-analysis was conducted to evaluate the effectiveness of MAPK inhibitors in ovarian carcinoma (OC) patients, showing that MEK inhibitors are the most promising single agents in (LGS)OC. Combination treatment with Raf-and MEK inhibitors in BRAFv600 mutated LGSOC had the greatest efficacy.

GYNECOLOGIC ONCOLOGY (2023)

Article Oncology

Perceived barriers and facilitators to health behaviors in European childhood cancer survivors: A qualitative PanCareFollowUp study

Eline Bouwman, Saskia M. F. Pluijm, Iridi Stollman, Vera Araujo-Soares, Nicole M. A. Blijlevens, Cecilia F. Follin, Jeanette F. Winther, Lars Hjorth, Tomas Kepak, Katerina Kepakova, Leontien C. M. Kremer, Monica Muraca, Helena J. H. van Der Pal, Carina Schneider, Anne Uyttebroeck, Gertrui Vercruysse, Rod C. Skinner, Morven C. Brown, Rosella P. M. G. J. Hermens, Jacqueline Loonen, PanCareFollowUp Consortium

Summary: This study aimed to assess the barriers and facilitators to health behavior adoption and maintenance in childhood cancer survivors. The study found that knowledge, time constraints, and unhealthy environments were common barriers, while education and available professional support were identified as key opportunities to promote health behavior adoption in childhood cancer survivors.

CANCER MEDICINE (2023)

Article Oncology

Evaluation of a remote monitoring app in head and neck cancer follow-up care

Cecile van de Weerd, Tom Ebbers, Donna E. M. Smilde, Julia J. van Tol-Geerdink, Robert P. Takes, Guido B. van den Broek, Rosella P. M. G. Hermens, Rudolf B. Kool

Summary: A remote monitoring app was developed for head and neck cancer follow-up during the SARS-CoV-2 pandemic. The usability and patients' experiences with the app were studied through a mixed-methods approach. The app was found to be user-friendly and made patients feel more in control, but there were some barriers that need to be resolved before it can be used in regular follow-up.

CANCER MEDICINE (2023)

No Data Available